Drapkin Kimberlee C 4

What Happened
Kimberlee C. Drapkin, a director of Acumen Pharmaceuticals, was granted two award-type awards on 2026-06-03: 35,500 restricted stock units (RSUs) and 53,250 derivative awards (reported as an acquisition at $0.00). Both awards were reported on a Form 4 filed 2026-06-05. The reported acquisition price for both items is $0.00 (i.e., these are grants/awards rather than open-market purchases).

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Grants: 35,500 RSUs (acquired at $0.00) and 53,250 derivative awards (acquired at $0.00).
• Shares/ownership after transaction: not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 35,500 are RSUs; each RSU converts to one common share upon vesting. Vesting occurs on the earlier of the first anniversary of grant or the 2027 annual stockholder meeting, subject to continuous service.
  • F2: The 53,250 are derivative (shares subject to an option); vesting follows the same schedule/conditions as F1.
• No indication of a sale, cash exercise, tax withholding, 10b5-1 plan, or other disposition in the excerpt.

Context
These awards are equity compensation grants, not open-market purchases or sales. RSUs represent a contingent right to receive shares if vesting conditions are met; the derivative award appears to be an option-like grant that also vests on a similar schedule. Such grants are common for directors and reflect compensation arrangements rather than immediate personal investment or liquidation.